FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2889909012> ?p ?o ?g. }

• W2889909012 endingPage "1359" @default.
• W2889909012 startingPage "1351" @default.
• W2889909012 abstract "No approved systemic therapy exists for von Hippel-Lindau disease, an autosomal dominant disorder with pleiotropic organ manifestations that include clear cell renal cell carcinomas; retinal, cerebellar, and spinal haemangioblastomas; pheochromocytomas; pancreatic serous cystadenomas; and pancreatic neuroendocrine tumours. We aimed to assess the activity and safety of pazopanib in patients with von Hippel-Lindau disease.In this non-randomised, single-centre, open-label, phase 2 trial, adult patients with clinical manifestations of von Hippel-Lindau disease were recruited from the University of Texas MD Anderson Cancer Center (Houston, TX, USA) and were treated with pazopanib (800 mg orally daily) for 24 weeks, with an option to continue treatment if desired by the patient and treating physician. Primary endpoints were the proportion of patients who achieved an objective response and safety in the per-protocol population. The objective response was measured for each patient and each lesion type. Radiographic assessments were done at baseline and every 12 weeks throughout the study. Activity and safety were assessed with continuous monitoring and a Bayesian design. This study is registered with ClinicalTrials.gov, number NCT01436227, and is closed to accrual.Between Jan 18, 2012, and Aug 10, 2016, we screened 37 patients with genetically confirmed or clinical features consistent with von Hippel-Lindau disease, of whom 31 eligible patients were treated with pazopanib. The proportion of patients who achieved an objective response was 42% (13 of 31 patients). By lesion sites responses were observed in 31 (52%) of 59 renal cell carcinomas, nine (53%) of 17 pancreatic lesions, and two (4%) of 49 CNS haemangioblastomas. Seven (23%) of 31 patients chose to stay on the treatment after 24 weeks. Four (13%) of 31 patients withdrew from the study because of grade 3 or 4 transaminitis, and three (10%) discontinued study treatment because of treatment intolerance with multiple intercurrent grade 1-2 toxicities. Treatment-related serious adverse events included one case each of appendicitis and gastritis and one patient had a fatal CNS bleed.Pazopanib was associated with encouraging preliminary activity in von Hippel-Lindau disease, with a side-effect profile consistent with that seen in previous trials. Pazopanib could be considered as a treatment choice for patients with von Hippel-Lindau disease and growing lesions, or to reduce the size of unresectable lesions in these patients. The safety and activity of pazopanib in this setting warrants further investigation.Novartis Inc and NIH National Cancer Institute core grant." @default.
• W2889909012 created "2018-09-27" @default.
• W2889909012 creator A5002650017 @default.
• W2889909012 creator A5007689146 @default.
• W2889909012 creator A5008668443 @default.
• W2889909012 creator A5010502061 @default.
• W2889909012 creator A5012403937 @default.
• W2889909012 creator A5017007258 @default.
• W2889909012 creator A5022629958 @default.
• W2889909012 creator A5027814049 @default.
• W2889909012 creator A5040390062 @default.
• W2889909012 creator A5047229451 @default.
• W2889909012 creator A5047703549 @default.
• W2889909012 creator A5062746651 @default.
• W2889909012 creator A5075931431 @default.
• W2889909012 creator A5085172191 @default.
• W2889909012 date "2018-10-01" @default.
• W2889909012 modified "2023-10-01" @default.
• W2889909012 title "Pazopanib in patients with von Hippel-Lindau disease: a single-arm, single-centre, phase 2 trial" @default.
• W2889909012 cites W1749022239 @default.
• W2889909012 cites W1860229144 @default.
• W2889909012 cites W1965472979 @default.
• W2889909012 cites W1972009030 @default.
• W2889909012 cites W1974031680 @default.
• W2889909012 cites W1977494495 @default.
• W2889909012 cites W1997507573 @default.
• W2889909012 cites W1999934840 @default.
• W2889909012 cites W2024355133 @default.
• W2889909012 cites W2028411874 @default.
• W2889909012 cites W2040219306 @default.
• W2889909012 cites W2044311723 @default.
• W2889909012 cites W2068555261 @default.
• W2889909012 cites W2082917554 @default.
• W2889909012 cites W2116949558 @default.
• W2889909012 cites W2132423292 @default.
• W2889909012 cites W2136434660 @default.
• W2889909012 cites W2136874505 @default.
• W2889909012 cites W2160888189 @default.
• W2889909012 cites W2162424705 @default.
• W2889909012 cites W2235086846 @default.
• W2889909012 cites W2244568679 @default.
• W2889909012 cites W2301077542 @default.
• W2889909012 cites W2320793255 @default.
• W2889909012 cites W2415766229 @default.
• W2889909012 cites W2551569844 @default.
• W2889909012 cites W2553083292 @default.
• W2889909012 cites W2564654074 @default.
• W2889909012 cites W2792204307 @default.
• W2889909012 doi "https://doi.org/10.1016/s1470-2045(18)30487-x" @default.
• W2889909012 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6338228" @default.
• W2889909012 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30236511" @default.
• W2889909012 hasPublicationYear "2018" @default.
• W2889909012 type Work @default.
• W2889909012 sameAs 2889909012 @default.
• W2889909012 citedByCount "55" @default.
• W2889909012 countsByYear W28899090122018 @default.
• W2889909012 countsByYear W28899090122019 @default.
• W2889909012 countsByYear W28899090122020 @default.
• W2889909012 countsByYear W28899090122021 @default.
• W2889909012 countsByYear W28899090122022 @default.
• W2889909012 countsByYear W28899090122023 @default.
• W2889909012 crossrefType "journal-article" @default.
• W2889909012 hasAuthorship W2889909012A5002650017 @default.
• W2889909012 hasAuthorship W2889909012A5007689146 @default.
• W2889909012 hasAuthorship W2889909012A5008668443 @default.
• W2889909012 hasAuthorship W2889909012A5010502061 @default.
• W2889909012 hasAuthorship W2889909012A5012403937 @default.
• W2889909012 hasAuthorship W2889909012A5017007258 @default.
• W2889909012 hasAuthorship W2889909012A5022629958 @default.
• W2889909012 hasAuthorship W2889909012A5027814049 @default.
• W2889909012 hasAuthorship W2889909012A5040390062 @default.
• W2889909012 hasAuthorship W2889909012A5047229451 @default.
• W2889909012 hasAuthorship W2889909012A5047703549 @default.
• W2889909012 hasAuthorship W2889909012A5062746651 @default.
• W2889909012 hasAuthorship W2889909012A5075931431 @default.
• W2889909012 hasAuthorship W2889909012A5085172191 @default.
• W2889909012 hasBestOaLocation W28899090122 @default.
• W2889909012 hasConcept C126322002 @default.
• W2889909012 hasConcept C141071460 @default.
• W2889909012 hasConcept C143998085 @default.
• W2889909012 hasConcept C2777472916 @default.
• W2889909012 hasConcept C2778439243 @default.
• W2889909012 hasConcept C2778560582 @default.
• W2889909012 hasConcept C2778822529 @default.
• W2889909012 hasConcept C2778886567 @default.
• W2889909012 hasConcept C2779134260 @default.
• W2889909012 hasConcept C2779490328 @default.
• W2889909012 hasConcept C2908647359 @default.
• W2889909012 hasConcept C535046627 @default.
• W2889909012 hasConcept C71924100 @default.
• W2889909012 hasConcept C90924648 @default.
• W2889909012 hasConcept C99454951 @default.
• W2889909012 hasConceptScore W2889909012C126322002 @default.
• W2889909012 hasConceptScore W2889909012C141071460 @default.
• W2889909012 hasConceptScore W2889909012C143998085 @default.
• W2889909012 hasConceptScore W2889909012C2777472916 @default.
• W2889909012 hasConceptScore W2889909012C2778439243 @default.
• W2889909012 hasConceptScore W2889909012C2778560582 @default.

• next